- Facebook Fiasco: 10 Things Underwriters Got Wrong
- Sticker Shock: What College Is Likely to Cost in 18 Years
- Marc Faber: 100% Chance of Global Recession
- Citigroup Lost $20 Million on Facebook IPO Trades
- Main Players in the Greek Election
- Many Greeks Moved Their Money Abroad Long Ago
- Bankia Asks Spain for $24 Billion Bailout
- European Consumers 'Hit With a One-Two Punch': Kilduff
- Still Like Facebook? There’s an ETF for That.
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
MOST SHARED
- Citigroup Lost $20 Million on Facebook IPO Trades
- Many Greeks Moved Their Money Abroad Long Ago
- S&P Cuts Ratings on Five Spanish Banks
- Are Investors Running Out of Safe Havens to Put Money?
- Reum: Successfully Marketing Liquor through Facebook
- CNBC Webinar: Competitive-Edge Technologies for Advanced Manufacturing
- Europe Fights Argentina's 'Protectionist' Import Rules
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Kansas City Fed President Steps Into Jamie Dimon Debate
- Facebook IPO Fiasco: 10 Things Underwriters Got Wrong
MOST POPULAR
HOT ON FACEBOOK
Pfizer Gets Approvable Letter for AIDS Drug, Scraps Cancer Trials
Text Size 
Pfizer said after markets closed Wednesday that U.S. health regulators will approve its novel AIDS drug called maraviroc once certain conditions have been met, although the world's biggest drugmaker did not elaborate on what was necessary to obtain an outright approval.
Pfizer [PFE
Loading...
()
] received a so-called approvable letter from the Food and Drug Administration for the twice-a-day pill that is the first drug designed to keep the HIV virus that causes AIDS from entering healthy immune cells. Older AIDS medicines attack the virus itself.
The company said it was in discussions with the FDA to address the agency's outstanding questions and finalize the product labeling as soon as possible.
Earlier Wednesday, Pfizer said it has ended trials of PF-3512676 in combination with cytotoxic chemotherapy as a treatment for lung cancer.
The company said this includes two Phase 3 and two Phase 2 clinical trials.
Pfizer said an interim analysis of the Phase 3 trials by an independent data safety monitoring committee (DSMC) showed there was no evidence that PF-3512676 produced additional clinical efficacy over that achieved with the standard cytotoxic chemotherapy regimen alone.
"The DSMC concluded that the risk-benefit profile did not justify continuation of the trials," the company said.
Pfizer said it licensed PF-3512676 from Coley Pharmaceutical Group in 2005. Coley shares nosedived [COLY
Loading...
()
] more than 55% Wednesday.
- The Nasdaq has suffered the most from the EU crisis showing there's risk in the usual tech stocks.
- Targeting more Millennials is just one of the items brewing for consumers in the world of spirits.
- It seems many people may need a reminder of how NOT to act on a plane. Here are a few tips.
- Here are some very unusual roadside stops along American highways that might peek your interest.
- How three generations of Americans are dealing with the finances of retirement.
Data is a real-time snapshot *Data is delayed at least 15 minutes
